An exploratory analysis shows a reduction in extrathoracic metastases and prolonged time to progression or death due to any metastases with durvalumab vs placebo.
Pembrolizumab plus concurrent chemoradiotherapy shows ongoing antitumor activity after about 5 years of follow-up in patients ...
Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...
A new Drosophila collection of Parkinsonism models reveals early synaptic cholinergic projection neuron dysfunction, linking synaptic failure to later dopaminergic decline, highlighting a role for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback